Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nektar Therapeutics ( (NKTR) ) has shared an announcement.
On June 30, 2025, Nektar Therapeutics announced an underwritten public offering of 4,255,320 shares of its common stock, priced at $23.50 per share, expected to close on July 2, 2025. The offering, managed by Jefferies LLC and other underwriters, is projected to yield approximately $93.7 million in net proceeds, with potential to increase to $107.8 million if additional shares are purchased. The funds are intended for general corporate purposes, including research and development and clinical advancement of drug candidates, potentially impacting the company’s financial standing and operational capabilities.
The most recent analyst rating on (NKTR) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
Nektar Therapeutics faces significant financial challenges, which weigh heavily on its overall score. However, positive technical indicators and promising developments in its drug pipeline, as highlighted in recent corporate events and the earnings call, provide some optimism. The stock’s valuation remains under pressure, reflecting the need for financial improvement.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company based in San Francisco, California, focusing on developing innovative treatments for autoimmune and chronic inflammatory diseases. Their lead product candidate, rezpegaldesleukin, is being evaluated in Phase 2b clinical trials for atopic dermatitis and alopecia areata. The company also has a pipeline that includes preclinical programs and investigational treatments aimed at enhancing the immune system’s ability to combat cancer.
Average Trading Volume: 1,495,347
Technical Sentiment Signal: Buy
Current Market Cap: $319.6M
For detailed information about NKTR stock, go to TipRanks’ Stock Analysis page.